Nothing Special   »   [go: up one dir, main page]

WO2008081331A3 - Enhancing the level of antibody expression by framework re-engineering - Google Patents

Enhancing the level of antibody expression by framework re-engineering Download PDF

Info

Publication number
WO2008081331A3
WO2008081331A3 PCT/IB2007/004379 IB2007004379W WO2008081331A3 WO 2008081331 A3 WO2008081331 A3 WO 2008081331A3 IB 2007004379 W IB2007004379 W IB 2007004379W WO 2008081331 A3 WO2008081331 A3 WO 2008081331A3
Authority
WO
WIPO (PCT)
Prior art keywords
framework
immunoglobulin
heavy
sequences
engineering
Prior art date
Application number
PCT/IB2007/004379
Other languages
French (fr)
Other versions
WO2008081331A2 (en
Inventor
Lei Yang
Pui Fan Wong
Original Assignee
Lei Yang
Pui Fan Wong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lei Yang, Pui Fan Wong filed Critical Lei Yang
Publication of WO2008081331A2 publication Critical patent/WO2008081331A2/en
Publication of WO2008081331A3 publication Critical patent/WO2008081331A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Methods for enhancing antibody expression by re-engineering immunoglobulins by selecting a set of framework sequences that provides high expression and high specific binding of a target antigen. The methods include providing a set of amino acid sequences corresponding to the heavy or light chain variable region framework segments derived from two or more immunoglobulin heavy or light chains, replacing the heavy or light chain framework segments of a parent immunoglobulin with sequences from the set of amino acid sequences to obtain framework re-engineered immunoglobulins. In some embodiments, the framework sequences selected for use in the re-engineered immunoglobulin are not all derived from the same immunoglobulin. The methods provide a new approach to humanizing antibodies.
PCT/IB2007/004379 2006-12-29 2007-12-31 Enhancing the level of antibody expression by framework re-engineering WO2008081331A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87803006P 2006-12-29 2006-12-29
US60/878,030 2006-12-29

Publications (2)

Publication Number Publication Date
WO2008081331A2 WO2008081331A2 (en) 2008-07-10
WO2008081331A3 true WO2008081331A3 (en) 2008-11-13

Family

ID=39589060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004379 WO2008081331A2 (en) 2006-12-29 2007-12-31 Enhancing the level of antibody expression by framework re-engineering

Country Status (1)

Country Link
WO (1) WO2008081331A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP2603720B1 (en) 2010-08-10 2016-04-13 Ross Europa GmbH Two part valve
KR102080535B1 (en) 2011-11-23 2020-02-24 메디뮨 엘엘씨 Binding molecules specific for her3 and uses thereof
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
CN113549152B (en) * 2021-07-22 2023-06-20 中国人民解放军空军军医大学 anti-BASIGIN humanized antibody and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002607A1 (en) * 2001-06-27 2003-01-09 Shawn Shui-On Leung Reducing immunogenicities of immunoglobulins by framework-patching
WO2006102095A2 (en) * 2005-03-18 2006-09-28 Medimmune, Inc. Framework-shuffling of antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002607A1 (en) * 2001-06-27 2003-01-09 Shawn Shui-On Leung Reducing immunogenicities of immunoglobulins by framework-patching
WO2006102095A2 (en) * 2005-03-18 2006-09-28 Medimmune, Inc. Framework-shuffling of antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FORSBERG GORAN ET AL.: "Identification of framework residues in s secreted recombinant antibody fragment that control production level and localization in Escherichia coli", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 19, 1997, pages 12430 - 12436, XP055354355 *
HORWITZ A. H. ET AL.: "Chimeric immunoglobulin light chains are secreted at different levels: influence of framwork-1 amino acids", MOLECULAR IMMUNOLOGY, vol. 31, no. 9, 1994, pages 683 - 692, XP023683141 *
LIANG RUI-AN ET AL.: "Framework-reengineering and its application in humanized antibody fSM03", CHINESE JOURNAL OF NEW DRUGS, vol. 15, no. 21, November 2006 (2006-11-01), pages 1832 - 1836 *

Also Published As

Publication number Publication date
WO2008081331A2 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
NZ607711A (en) Antibodies directed to her-3 and uses thereof
NZ601342A (en) Antibodies that bind il-4 and/or il-13 and their uses
NZ584838A (en) Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
ATE452147T1 (en) ANTIBODIES WITH CORRECTED CDR
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
AR052065A1 (en) DIRECTED ANTIBODIES AGAINST ANGIOPOYETINA-2 AND USES OF THE SAME
TW200801040A (en) Binding proteins specific for insulin-like growth factors and uses thereof
RS54113B1 (en) Compositions and methods for antibodies against complement protein c5
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2006113643A3 (en) High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
RS54197B1 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
RS53760B1 (en) Human antibodies that bind mesothelin, and uses thereof
NO20074867L (en) Antibodies to CCR5 and uses thereof
WO2008112004A3 (en) ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
NZ596295A (en) Anti-5T4 antibodies and uses thereof
IL184103A0 (en) Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
NO20066052L (en) Anti-CD3 antibodies and methods for their use
NZ623706A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
NZ597447A (en) Humanised antibodies to toll-like receptor 2 and uses thereof
NZ585622A (en) Hepatitis c virus antibodies
WO2008081331A3 (en) Enhancing the level of antibody expression by framework re-engineering
WO2006039258A3 (en) Human antibodies against parathyroid hormone

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2009543543

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07872050

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07872050

Country of ref document: EP

Kind code of ref document: A2